IOVANCE BIOTHERAPEUTICS, INC. (IOVA) Insider Trading & SEC Filings

Updated Jul 16, 2026 · Last SEC filing 2026-06-18

IOVANCE BIOTHERAPEUTICS, INC. (IOVA) has filed 14 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-06-18. 3 Form 8-K material event filings were reported by IOVA in the last 90 days. InsiderAlpha tracks every IOVA SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.

About IOVANCE BIOTHERAPEUTICS, INC. (IOVA)

SEC CIK	0001425205

90-Day SEC Filing Activity

Form 4 filings (90d)	14
Form 8-K filings (90d)	3
Latest Form 4 filing	2026-06-18

Recent IOVA Insider Transactions (Form 4)

Date	Insider	Role	Transaction	Shares	Price	Value	Filing
2026-06-05	GRAF FINCKENSTEIN FRIEDRICH	Chief Medical Officer	F — Tax withholding / forfeiture	4.0K	$4.23	$17K	SEC
2026-06-05	Puri Raj K.	Chief Regulatory Officer	M — Option exercise	9.8K	$0.00	—	SEC
2026-06-05	BILINSKY IGOR	Chief Operating Officer	F — Tax withholding / forfeiture	4.0K	$4.23	$17K	SEC
2026-06-05	GRAF FINCKENSTEIN FRIEDRICH	Chief Medical Officer	M — Option exercise	7.8K	$0.00	—	SEC
2026-06-05	Vogt Frederick G	Interim CEO & General Counsel	M — Option exercise	15.6K	$0.00	—	SEC
2026-06-05	Vogt Frederick G	Interim CEO & General Counsel	F — Tax withholding / forfeiture	6.6K	$4.23	$28K	SEC
2026-06-05	Puri Raj K.	Chief Regulatory Officer	F — Tax withholding / forfeiture	3.8K	$4.23	$16K	SEC
2026-06-05	BILINSKY IGOR	Chief Operating Officer	M — Option exercise	7.8K	$0.00	—	SEC
2026-06-01	GRAF FINCKENSTEIN FRIEDRICH	Chief Medical Officer	M — Option exercise	8.8K	$0.00	—	SEC
2026-06-01	Vogt Frederick G	Interim CEO & General Counsel	F — Tax withholding / forfeiture	17.7K	$3.96	$70K	SEC
2026-06-01	GRAF FINCKENSTEIN FRIEDRICH	Chief Medical Officer	F — Tax withholding / forfeiture	4.5K	$3.96	$18K	SEC
2026-06-01	Vogt Frederick G	Interim CEO & General Counsel	M — Option exercise	41.7K	$0.00	—	SEC
2026-06-01	Puri Raj K.	Chief Regulatory Officer	M — Option exercise	5.5K	$0.00	—	SEC
2026-06-01	BILINSKY IGOR	Chief Operating Officer	M — Option exercise	8.8K	$0.00	—	SEC
2026-06-01	Puri Raj K.	Chief Regulatory Officer	F — Tax withholding / forfeiture	2.5K	$3.96	$10K	SEC

All transactions sourced from SEC EDGAR Form 4 filings for IOVANCE BIOTHERAPEUTICS, INC. (IOVA). Updated in real time as new filings are submitted to the SEC.

Most-Active IOVA Insiders — Last 90 Days

Insider	Form 4 filings	Total transaction value
Puri Raj K.	7	$26K
Vogt Frederick G	6	$98K
BILINSKY IGOR	6	$35K
GRAF FINCKENSTEIN FRIEDRICH	6	$35K
Kirby Daniel Gordon	3	$9K

Recent IOVA Form 8-K Material Events

2026-07-02 — Item 8.01, 9.01 [SEC]
2026-06-10 — Item 5.07, 8.01, 9.01 [SEC]
2026-05-07 — Item 2.02, 9.01 [SEC]
2026-03-20 — Item 5.02 · Leadership · neutral [SEC]
Wendy Yarno, a member of Iovance Biotherapeutics' Board of Directors, announced her retirement from the Board effective at the Company's annual meeting in June 2026. The departure is not due to any disagreement with the Company and is a routine board transition.
2026-02-24 — Item 2.02, 8.01, 9.01 · Earnings · neutral [SEC]
Iovance Biotherapeutics issued a press release on February 24, 2026 announcing Q4 2025 and full-year 2025 financial results along with an update on recent corporate developments. The company also updated its corporate presentation for use at healthcare conferences and investor me

Recent Insider Filings

2026-06-18 — WEISER MICHAEL (Director)
2026-06-18 — Dukes Iain D. (Director)
2026-06-18 — Countouriotis Athena (Director)
2026-06-18 — Maynard Ryan D (Director)
2026-06-18 — Puri Raj K. (Chief Regulatory Officer)

Form 4 Transaction Code Reference

SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in IOVA insider filings:

P	Open-market purchase by the insider
S	Open-market sale by the insider
A	Grant, award, or other acquisition from the issuer
M	Exercise or conversion of derivative security (e.g. options)
F	Payment of exercise price or tax liability via share withholding
G	Bona-fide gift of securities
D	Disposition to the issuer (e.g. share buyback participation)
J	Other acquisition or disposition
X	Exercise of in-the-money or at-the-money derivative security
C	Conversion of derivative security
V	Transaction voluntarily reported earlier than required

IOVA Insider Trading — FAQ

What is the latest insider trade for IOVA?: IOVANCE BIOTHERAPEUTICS, INC. (IOVA) had 14 insider filings in the last 90 days, with the most recent on 2026-06-18. InsiderAlpha tracks every Form 4, 10-K, 10-Q, and 8-K filing in real time.
How many insiders are buying IOVA stock?: 0 insider purchases of IOVA were filed in the last 90 days.
How many insiders are selling IOVA stock?: 0 insider sales of IOVA were filed in the last 90 days.
Where can I see IOVA SEC filings (Form 4, 10-K, 10-Q, 8-K)?: InsiderAlpha aggregates every IOVA SEC filing — Form 4 insider transactions, 10-K and 10-Q quarterly reports, and 8-K material event disclosures — in one timeline.

Learn More

Open the live IOVA dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.